Showing results (321-330 of 367) with videos related to
Sort By:
Pageof 37
Cancer Research and Treatment|August 5, 2016
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study ResultsYeon Hee Park, Tae Yong Kim, Young-Hyuck Im, et al.American Journal of Hematology|February 3, 2007
Nongastric marginal zone B-cell lymphoma: analysis of 247 casesSung Yong Oh, Baek-Yeol Ryoo, Won Seog Kim, et al.European Journal of Cancer (Oxford, England : 1990)|November 4, 2017
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancerYeon Hee Park, Seock-Ah Im, Sung-Bae Kim, et al.Cancer Research and Treatment|November 18, 2022
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, et al.Nature Medicine|January 21, 2025
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trialFatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al.Cancer Communications (London, England)|May 30, 2019
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)Ji-Yeon Kim, Seri Park, Seock-Ah Im, et al.International Journal of Cancer|July 7, 2018
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trialYeon Hee Park, Kyung-Hun Lee, Joo Hyuk Sohn, et al.Oncology Reports|July 14, 2005
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factorSeock-Ah Im, Sung-Bae Kim, Moon Hee Lee, et al.Cytokine|March 26, 2021
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)Ju Won Kim, Soohyeon Lee, Hye Sook Kim, et al.Nature Medicine|October 8, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trialShanu Modi, William Jacot, Hiroji Iwata, et al.Pageof 37